Related Experiment Videos
[Can PSA density predict the response to alpha-blockers in benign prostatic hyperplasia?]
G Server Pastor1, J A Nicolás Torralba, V Bañón Pérez
1Servicio de Urología, Hospital Universitario Virgen de la Arrixaca, Murcia.
Actas Urologicas Espanolas
|May 11, 2001
Summary
Lower prostate-specific antigen density (PSAd) indicates a higher stromal/epithelial ratio, predicting better response to alpha-blocker therapy in benign prostatic hyperplasia (BPH) patients.
Area of Science:
- Urology
- Andrology
- Pharmacology
Context:
- Benign prostatic hyperplasia (BPH) involves glandular and stromal growth.
- Adrenoceptors are primarily located in the fibromuscular stroma.
- A higher stromal/epithelial ratio correlates with increased alpha-blocker efficacy.
Purpose:
- To investigate the utility of prostate-specific antigen density (PSAd) in predicting alpha-blocker response in BPH.
- To establish PSAd as an indirect estimator of the stromal/epithelial ratio.
Summary:
- 75 BPH patients with bladder outlet obstruction received alfuzosin for 3 months.
- Patients were assessed pre- and post-treatment using IPSS and uroflowmetry.
- A statistically significant improvement in parameters was observed in all patients, with a notably better response in those with lower PSAd.
Impact:
- Prostate-specific antigen density (PSAd) is a useful predictor of alpha-blocker treatment response in BPH.
- PSAd serves as a valuable, non-invasive method to estimate the stromal/epithelial ratio.
- This finding can guide therapeutic decisions for BPH management.